Galapagos NV ADR (GLPG) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Galapagos NV ADR (GLPG) has a cash flow conversion efficiency ratio of -0.025x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-82.75 Million) by net assets ($3.25 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market value of Galapagos NV ADR for the company's overall valuation and market capitalisation.
Galapagos NV ADR - Cash Flow Conversion Efficiency Trend (2004–2025)
This chart illustrates how Galapagos NV ADR's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Galapagos NV ADR Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Galapagos NV ADR ranked by their cash flow conversion efficiency. Explore Galapagos NV ADR earnings quality ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Reysas Gayrimenkul Yatirim Ortakligi AS
IS:RYGYO
|
0.012x |
|
Mesoblast Ltd
AU:MSB
|
-0.007x |
|
GH Research PLC
NASDAQ:GHRS
|
-0.042x |
|
Meshek Energy-Renewable Energies Ltd
TA:MSKE
|
0.010x |
|
A.F.P. Provida
SN:PROVIDA
|
0.022x |
|
Azad Engineering Limited
NSE:AZAD
|
-0.050x |
|
Cury Construtora e Incorporadora S.A
SA:CURY3
|
0.165x |
|
SES S. A.
PA:SESG
|
0.174x |
Annual Cash Flow Conversion Efficiency for Galapagos NV ADR (2004–2025)
The table below shows the annual cash flow conversion efficiency of Galapagos NV ADR from 2004 to 2025. View current stock price of Galapagos NV ADR for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $3.23 Billion | $-189.23 Million | -0.059x | +47.04% |
| 2024-12-31 | $2.90 Billion | $-320.03 Million | -0.110x | +23.93% |
| 2023-12-31 | $2.80 Billion | $-405.97 Million | -0.145x | +26.71% |
| 2022-12-31 | $2.53 Billion | $-500.54 Million | -0.198x | -3.96% |
| 2021-12-31 | $2.64 Billion | $-503.83 Million | -0.191x | -19.10% |
| 2020-12-31 | $2.67 Billion | $-427.34 Million | -0.160x | -112.79% |
| 2019-12-31 | $2.88 Billion | $3.60 Billion | 1.251x | +1166.08% |
| 2018-12-31 | $1.21 Billion | $-142.47 Million | -0.117x | +19.24% |
| 2017-12-31 | $1.01 Billion | $-147.03 Million | -0.145x | -146.04% |
| 2016-12-31 | $758.70 Million | $239.40 Million | 0.316x | +200.51% |
| 2015-12-31 | $365.00 Million | $-114.59 Million | -0.314x | +14.35% |
| 2014-12-31 | $206.13 Million | $-75.56 Million | -0.367x | -11835.82% |
| 2013-12-31 | $167.14 Million | $522.00K | 0.003x | -99.42% |
| 2012-12-31 | $118.45 Million | $64.10 Million | 0.541x | +634.28% |
| 2011-12-31 | $118.38 Million | $-11.99 Million | -0.101x | +19.01% |
| 2010-12-31 | $148.51 Million | $-18.57 Million | -0.125x | -316.03% |
| 2009-12-31 | $108.88 Million | $6.30 Million | 0.058x | +159.47% |
| 2008-12-31 | $84.32 Million | $-8.21 Million | -0.097x | -2687.95% |
| 2007-12-31 | $98.63 Million | $371.00K | 0.004x | +104.43% |
| 2006-12-31 | $109.54 Million | $-9.31 Million | -0.085x | -33.68% |
| 2005-12-31 | $61.14 Million | $-3.89 Million | -0.064x | +75.68% |
| 2004-12-31 | $10.37 Million | $-2.71 Million | -0.261x | -- |
About Galapagos NV ADR
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product c… Read more